EUDA Accelerates Longevity Strategy with Launch of Comprehensive Stem Cell Therapy Platform and First Clinic in Shenzhen

Core Insights - EUDA Health Holdings Limited is accelerating its longevity and regenerative medicine strategy by launching a comprehensive stem cell therapy platform and establishing its first clinic in Shenzhen, China [1][4] Group 1: Strategic Developments - The company has acquired distribution rights for T-cell immunotherapies from Shenzhen Inno Immune Co. Ltd., which specializes in autologous cellular therapeutics [2] - EUDA intends to acquire GO POSB Organoids Pte Ltd., a biotechnology company based in Singapore [2] Group 2: Facility and Technology Enhancements - EUDA is upgrading Shenzhen Inno's cGMP facility to create a state-of-the-art production and innovation center for stem cell treatments, incorporating GO POSB's iPSC technology and advanced stem cell technologies from Japanese partners [3] - The upgraded facility will support iPSC expansion, stem cell preparation, immune cell therapies, and the development of new treatments focused on immune health, skin health, and healthy aging [3] Group 3: Clinic Establishment and Services - A new longevity clinic has been established in Shenzhen in partnership with KB International Ltd., which will introduce Japanese longevity healthcare technologies [4] - The clinic will offer services aimed at enhancing longevity, slowing biological aging, strengthening immunity, and providing long-term health planning [4] Group 4: Company Vision and Market Position - The company aims to become a market leader in non-invasive and preventive healthcare, focusing on the fast-growing longevity sector to address the healthcare needs of over 1.8 billion people in the region [6] - EUDA is positioned to lead the transformation of regional healthcare from reactive treatment to proactive, longevity-focused care [6]